Regenxbio (RGNX) Gains from Investment Securities (2014 - 2025)

Regenxbio's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at $122000.0 for Q4 2025.

• In Q4 2025, Gains from Investment Securities fell 98.14% year-over-year to $122000.0; the TTM figure through Dec 2025 stood at $12.5 million (down 2.64% YoY), while the FY2025 annual figure was $801000.0, down 91.99% from the prior year.
• Gains from Investment Securities was $122000.0 for Q4 2025 at Regenxbio, down from $755306.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $11.8 million in Q1 2025 to a low of -$4.1 million in Q4 2021.
• Historically, Gains from Investment Securities has averaged $3.2 million across 5 years, with a median of $2.1 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Gains from Investment Securities plunged 5823.61% in 2021, then surged 2706.5% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$4.1 million in 2021, then surged by 111.19% to $461000.0 in 2022, then jumped by 753.15% to $3.9 million in 2023, then jumped by 66.69% to $6.6 million in 2024, then tumbled by 98.14% to $122000.0 in 2025.
• The last three Gains from Investment Securities figures came in at $122000.0 (Q4 2025), $755306.0 (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.